β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis
暂无分享,去创建一个
Margarete Odenthal | M. Odenthal | H. Varnholt | H. Dienes | U. Drebber | U. Töx | Heike Varnholt | Uta Drebber | Hans-Peter Dienes | Ingo Strack | Sigrid Schulte | Stephanie Schievenbusch | Ulrich Töx | Katharina Wendland | Hans-Michael Steffen | H. Steffen | S. Schievenbusch | I. Strack | S. Schulte | K. Wendland
[1] C. Anesini,et al. Modulatory effect of the adrenergic system upon fibroblast proliferation: participation of beta 3-adrenoceptors. , 2002, Autonomic & autacoid pharmacology.
[2] P. Angus,et al. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. , 2002, Gastroenterology.
[3] Jaung-Geng Lin,et al. Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells. , 2004, Cardiovascular research.
[4] M. Pekalski,et al. Epithelial–mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease , 2008, Laboratory Investigation.
[5] R. Kalluri,et al. Epithelial-mesenchymal transition and its implications for fibrosis. , 2003, The Journal of clinical investigation.
[6] C. Benz,et al. [Primary sclerosing cholangitis]. , 2000, Der Internist.
[7] N. Sinelli,et al. Hepatic fibrogenesis requires sympathetic neurotransmitters , 2004, Gut.
[8] D. Brenner,et al. Fibrogenesis of parenchymal organs. , 2008, Proceedings of the American Thoracic Society.
[9] Jochen Wilhelm,et al. Laser-microdissection for cell type- and compartment-specific analyses on genomic and proteomic level. , 2006, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[10] D. Kershenobich,et al. Hepatic Fibrosis , 1955, British medical journal.
[11] R. Chapman,et al. An update on primary sclerosing cholangitis , 2008, Current opinion in gastroenterology.
[12] Christopher J. Parsons,et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct–ligated rats , 2005, Hepatology.
[13] B. Shakiba,et al. Attenuation of hepatic fibrosis through captopril and enalapril in the livers of bile duct ligated rats. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[14] M. Clozel,et al. Role of endothelin in fibrosis and anti‐fibrotic potential of bosentan , 2005, Annals of medicine.
[15] H. Tilg,et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2004, Gastroenterology.
[16] Y. Wei,et al. Effect of Losartan, an Angiotensin II Antagonist, on Hepatic Fibrosis Induced by CCl4 in Rats , 2004, Digestive Diseases and Sciences.
[17] N. Sinelli,et al. Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury , 2003, Hepatology.
[18] Y. Matsuzawa,et al. Angiotensin II stimulates the nuclear translocation of Smad2 and induces PAI-1 mRNA in rat hepatic stellate cells. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.
[19] A. Diehl,et al. Sympathetic nervous system regulation of liver repair. , 2004, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.
[20] U. Töx,et al. Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension. , 2006, Current medicinal chemistry.
[21] H. Zimmer,et al. Comitogenic effect of catecholamines on rat cardiac fibroblasts in culture. , 2000, Cardiovascular research.
[22] N. Sinelli,et al. Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. , 2003, Biochemical and biophysical research communications.
[23] R. DePinho,et al. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. , 2006, Cancer research.
[24] Z. Goodman. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. , 2007, Journal of hepatology.
[25] V. N. Finelli,et al. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. , 1981, Analytical biochemistry.
[26] R. Schwabe,et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. , 2006, Journal of hepatology.
[27] F. Lammert,et al. Spontaneous cholecysto‐ and hepatolithiasis in Mdr2−/− mice: A model for low phospholipid‐associated cholelithiasis , 2004, Hepatology.
[28] M. Vidaud,et al. INHIBITION OF LIVER FIBROGENESIS THROUGH NORADRENERGIC ANTAGONISM. , 2004 .
[29] K. Lindor,et al. Primary sclerosing cholangitis. , 2008, Hepatology.
[30] D. Schuppan,et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. , 2000, Gastroenterology.
[31] Division on Earth. Guide for the Care and Use of Laboratory Animals , 1996 .
[32] R. Voswinckel,et al. Bone marrow transplantation demonstrates medullar origin of CD34+ fibrocytes and ameliorates hepatic fibrosis in Abcb4−/− mice , 2010, Hepatology.
[33] K. Nakamura,et al. Neuropeptide Y stimulates bile secretion via Y1 receptor in the left dorsal vagal complex in rats , 1998, Hepatology.
[34] A. Groen,et al. The role of mdr2 P‐glycoprotein in hepatobiliary lipid transport , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] D. Brenner,et al. Mechanisms of Fibrogenesis , 2008, Experimental biology and medicine.
[36] M. Odenthal,et al. Hepatocyte expression of angiotensin II type 1 receptor is downregulated in advanced human liver fibrosis , 2009, Liver international : official journal of the International Association for the Study of the Liver.